Track topics on Twitter Track topics that are important to you
European regulators have granted Voluntis CE mark approval for a new version of its Insulia software app, which makes insulin -More-
Regulatory News: Voluntis (Paris:VTX) (Euronext Paris, Mnemo: VTX - ISIN: FR0004183960), a company specialized in digital therapeutics, announces today that it has...
Regulatory News: Voluntis (Euronext Paris, Ticker: VTX ISIN: FR0004183960) (Paris:VTX), a company specializing in digital therapeutics, announces Roche Pharma France's decision not to pursue ZEMY'...
The June 25th Webinar to Discuss Best Practices for Initiating and Managing Insulin Therapy Across the Continuum of Care. Despite advances in treatment and clear guidel...
Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage their treatment every day, thus improving real-world outcomes. Combining...
We have published hundreds of Voluntis news stories on BioPortfolio along with dozens of Voluntis Clinical Trials and PubMed Articles about Voluntis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Voluntis Companies in our database. You can also find out about relevant Voluntis Drugs and Medications on this site too.
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...